Gerben P. Bootsma - Concepedia

Author

Gerben P. Bootsma

Radboud University Nijmegen

Also Known As

G BOOTSMA, G P Bootsma, G. Bootsma, Gerben Bootsma, Gerben P Bootsma, Gerben P. Bootsma

Publications

261

Citations

H-Index

Concepts

All Affiliations

Radboud University Nijmegen Jeroen Bosch Ziekenhuis Zuyderland Medisch Centrum Isala The Netherlands Cancer Institute

About

Gerben P. Bootsma is an author at Radboud University Nijmegen specializing in health sciences, medicine, and cancer chemotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	2	2	110
2	Medicine	2	2	110
3	Engineering	1	1	52
4	Allergy	1	1	63
5	Computer Science	1	1	52

Gerben P. Bootsma

Publications

242

Citations

H-Index

Page 1

	Year	Citations
Fluticasone propionate does not influence bone metabolism in contrast to beclomethasone dipropionate. Gerben P. Bootsma, P.N.R. Dekhuijzen, Jan Festen, American Journal of Respiratory and Critical Care Medicine AsthmaPharmacotherapyGlucocorticoidOsteoporosisOrthopaedic Surgery	1996	63
Field Operational Test "The Assisted Driver" Tom Alkim, Gerben P. Bootsma, Serge Hoogendoorn IEEE Intelligent Vehicles Symposium EngineeringSafety ScienceAdvanced Driver-assistance SystemData ScienceDriver Behavior	2007	52
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial Cornedine J. de Gooijer, Vincent van der Noort, Jos A. Stigt, The Lancet Respiratory Medicine First-line ChemotherapySwitch-maintenance GemcitabineMalignant DiseaseMedicineMalignant Mesothelioma	2021	47
Comparison of fluticasone propionate and beclomethasone dipropionate on direct and indirect measurements of bronchial hyperresponsiveness in patients with stable asthma. Gerben P. Bootsma, P.N.R. Dekhuijzen, Jan Festen, Thorax	1995	44
Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response Floris Dammeijer, Cornedine J. de Gooijer, Mandy van Gulijk, EBioMedicine	2021	26
Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19) Sjaak A. Burgers, C. de Gooijer, Robin Cornelissen, Annals of Oncology	2019	10

Page 1